Old West Investment Management LLC decreased its position in ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 9.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,414 shares of the biotechnology company’s stock after selling 3,004 shares during the quarter. Old West Investment Management LLC’s holdings in ZIOPHARM Oncology were worth $182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in ZIOP. Amalgamated Bank increased its stake in ZIOPHARM Oncology by 12.9% in the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 1,924 shares during the last quarter. Mission Wealth Management LLC bought a new stake in ZIOPHARM Oncology in the 1st quarter worth approximately $108,000. BB&T Securities LLC bought a new stake in ZIOPHARM Oncology in the 2nd quarter worth approximately $112,000. Oppenheimer & Co. Inc. increased its stake in ZIOPHARM Oncology by 50.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 6,000 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in ZIOPHARM Oncology by 7.5% in the 2nd quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 1,673 shares during the last quarter. 41.94% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have issued reports on the company. ValuEngine downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, HC Wainwright set a $10.00 target price on ZIOPHARM Oncology and gave the company a “buy” rating in a research report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $13.17.

TRADEMARK VIOLATION WARNING: “Old West Investment Management LLC Trims Holdings in ZIOPHARM Oncology Inc (ZIOP)” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/23/old-west-investment-management-llc-trims-holdings-in-ziopharm-oncology-inc-ziop.html.

ZIOPHARM Oncology Inc (ZIOP) traded up 1.82% during trading on Friday, hitting $6.17. The stock had a trading volume of 805,935 shares. The company’s 50 day moving average is $5.85 and its 200-day moving average is $6.25. ZIOPHARM Oncology Inc has a 12 month low of $4.84 and a 12 month high of $7.88. The company’s market cap is $867.70 million.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The company had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. During the same period in the prior year, the business posted ($1.01) EPS. ZIOPHARM Oncology’s revenue for the quarter was down 5.9% compared to the same quarter last year. On average, equities research analysts predict that ZIOPHARM Oncology Inc will post ($0.56) earnings per share for the current year.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc (NASDAQ:ZIOP).

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.